1982
The contribution of amphetamine metabolites of (−)-deprenyl to its antiparkinsonian properties
Elsworth J, Sandler M, Lees A, Ward C, Stern G. The contribution of amphetamine metabolites of (−)-deprenyl to its antiparkinsonian properties. Journal Of Neural Transmission 1982, 54: 105-110. PMID: 6809891, DOI: 10.1007/bf01249283.Peer-Reviewed Original Research
1977
DEPRENYL IN PARKINSON'S DISEASE
Lees A, Kohout L, Shaw K, Stern G, Elsworth J, Sandler M, Youdim M. DEPRENYL IN PARKINSON'S DISEASE. The Lancet 1977, 310: 791-795. PMID: 71602, DOI: 10.1016/s0140-6736(77)90725-5.Peer-Reviewed Original ResearchConceptsParkinson's diseaseDouble-blind crossover trialDoses of levodopaEarly morning akinesiaPeripheral decarboxylase inhibitorLevodopa-induced dyskinesiaTotal daily dosesMajority of patientsIdiopathic Parkinson's diseaseDose akinesiaUntreated patientsCrossover trialDosage reductionDaily dosesDecarboxylase inhibitorTherapeutic effectCheese effectLarge dosesPatientsLevodopaAlternate daysAkinesiaDeprenylDiseaseB inhibitor